Presented by: University of Kentucky Department of Pathology

 

“ Renal Cell Carcinoma: Why Pathology Drives Treatment Decisions"

 

      Zin Myint, M.D.

Assistant Professor, Medical Oncology

University of Kentucky

Thursday, January 15, 2026

12:00 – 1:00pm

 

In-Person MS 147 or Zoom: http://us06web.zoom.us/j/89110280273? pwd=ybybn06jFDKtJzTCALTtz15lG8vhKV.1We

PASSCODE: 281106

 

 

 

 Use the QR code to register for this Grand Rounds if you have not already registered.

At the completion of this lecture attendees should be able to:

 

  • Summarize the WHO molecular classification of RCC and its clinical relevance
  • Describe the role of adjuvant immunotherapy in high-risk RCC
  • Outline contemporary systemic management strategies for RCC
  • Discuss established and emerging biomarkers in RCC
  • Recognize key therapeutic considerations in non-clear cell RCC
Session date: 
01/15/2026 - 12:30pm EST to 02/12/2026 - 10:59pm EST
Location: 
MS 147
800 Rose Street
Lexington, KY 40536
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
    UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
Please login or register to take this course.